Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Vis Exp ; (158)2020 04 09.
Article in English | MEDLINE | ID: mdl-32338647

ABSTRACT

Two-dimensional (2D) cell cultures do not mimic in vivo tumor growth satisfactorily. Therefore, three-dimensional (3D) culture spheroid models were developed. These models may be particularly important in the field of neuro-oncology. Indeed, brain tumors have the tendency to invade the healthy brain environment. We describe herein an ideal 3D glioblastoma spheroid-based assay that we developed to study tumor invasion. We provide all technical details and analytical tools to successfully perform this assay.


Subject(s)
Brain Neoplasms/pathology , Cell Culture Techniques/methods , Glioblastoma/pathology , Imaging, Three-Dimensional/methods , Spheroids, Cellular/pathology , Humans
2.
Nat Commun ; 8(1): 1571, 2017 11 17.
Article in English | MEDLINE | ID: mdl-29146996

ABSTRACT

CXCR3 plays important roles in angiogenesis, inflammation, and cancer. However, the precise mechanism of regulation and activity in tumors is not well known. We focused on CXCR3-A conformation and on the mechanisms controlling its activity and trafficking and investigated the role of CXCR3/LRP1 cross talk in tumor cell invasion. Here we report that agonist stimulation induces an anisotropic response with conformational changes of CXCR3-A along its longitudinal axis. CXCR3-A is internalized via clathrin-coated vesicles and recycled by retrograde trafficking. We demonstrate that CXCR3-A interacts with LRP1. Silencing of LRP1 leads to an increase in the magnitude of ligand-induced conformational change with CXCR3-A focalized at the cell membrane, leading to a sustained receptor activity and an increase in tumor cell migration. This was validated in patient-derived glioma cells and patient samples. Our study defines LRP1 as a regulator of CXCR3, which may have important consequences for tumor biology.


Subject(s)
Brain Neoplasms/pathology , Cell Movement/physiology , Glioblastoma/pathology , Low Density Lipoprotein Receptor-Related Protein-1/metabolism , Receptors, CXCR3/metabolism , Animals , Cell Membrane/metabolism , Chick Embryo , Gene Expression Regulation, Neoplastic , HEK293 Cells , Humans , Low Density Lipoprotein Receptor-Related Protein-1/genetics , Male , Mice , Mice, Knockout , Neoplasm Invasiveness/pathology , Protein Binding , Protein Transport/physiology , Spheroids, Cellular , Tumor Cells, Cultured
3.
ACS Chem Biol ; 12(11): 2767-2778, 2017 11 17.
Article in English | MEDLINE | ID: mdl-28945356

ABSTRACT

CXCL4 chemokines have antiangiogenic properties, mediated by different mechanisms, including CXCR3 receptor activation. Chemokines have distinct oligomerization states that are correlated with their biological functions. CXCL4 exists as a stable tetramer under physiological conditions. It is unclear whether the oligomerization state impacts CXCL4-receptor interaction. We found that the CXCL4 tetramer is sensitive to pH and salt concentration. Residues Glu28 and Lys50 were important for tetramer formation, and the first ß-strand and the C-terminal helix are critical for dimerization. By mutating the critical residues responsible for oligomerization, we generated CXCL4 mutants that behave as dimers or monomers under neutral/physiological conditions. The CXCL4 monomer acts as the minimal active unit for interacting CXCR3A, and sulfation of N-terminal tyrosine residues on the receptor is important for binding. Noticeably, CXCL4L1, a CXCL4 variant that differs by three residues in the C-terminal helix, could activate CXCR3A. CXCL4L1 showed a higher tendency to dissociate into monomers, but native CXCL4 did not. This result indicates that monomeric CXCL4 behaves like CXCL4L1. Thus, in this chemokine family, being in the monomeric state seems critical for interaction with CXCR3A.


Subject(s)
Platelet Factor 4/metabolism , Receptors, CXCR3/metabolism , Cell Line , Humans , Hydrogen-Ion Concentration , Kinetics , Models, Molecular , Platelet Factor 4/chemistry , Protein Binding , Protein Conformation , Protein Multimerization , Receptors, CXCR3/chemistry
4.
Oncotarget ; 4(12): 2302-16, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24327603

ABSTRACT

Kinesin motor proteins exert essential cellular functions in all eukaryotes. They control mitosis, migration and intracellular transport through interaction with microtubules. Small molecule inhibitors of the mitotic kinesin KiF11/Eg5 are a promising new class of anti-neoplastic agents currently evaluated in clinical cancer trials for solid tumors and hematological malignancies. Here we report induction of Eg5 and four other mitotic kinesins including KIF20A/Mklp2 upon stimulation of in vivo angiogenesis with vascular endothelial growth factor-A (VEGF-A). Expression analyses indicate up-regulation of several kinesin-encoding genes predominantly in lymphoblasts and endothelial cells. Chemical blockade of Eg5 inhibits endothelial cell proliferation and migration in vitro. Mitosis-independent vascular outgrowth in aortic ring cultures is strongly impaired after Eg5 or Mklp2 protein inhibition. In vivo, interfering with KIF11/Eg5 function causes developmental and vascular defects in zebrafish and chick embryos and potent inhibition of tumor angiogenesis in experimental tumor models. Besides blocking tumor cell proliferation, impairing endothelial function is a novel mechanism of action of kinesin inhibitors.


Subject(s)
Glioma/blood supply , Kinesins/antagonists & inhibitors , Animals , Cell Growth Processes/drug effects , Cell Line, Tumor , Chick Embryo , Chorioallantoic Membrane/blood supply , Chorioallantoic Membrane/drug effects , Gene Expression/drug effects , Glioma/drug therapy , Glioma/enzymology , Human Umbilical Vein Endothelial Cells , Humans , Kinesins/genetics , Kinesins/metabolism , Mice , Mitosis/drug effects , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/enzymology , Quinazolines/pharmacology , Recombinant Proteins/pharmacology , Thiones/pharmacology , Vascular Endothelial Growth Factor A/pharmacology , Zebrafish
SELECTION OF CITATIONS
SEARCH DETAIL
...